In the high-grade subgroup, four-year prostate cancer-specific mortality (PCSM) was higher in patients with PSA ≤ 5 ng/mL than in those with PSA 5.1–10 ng/mL. This evidence concerns the gene KLK3 and prostate carcinoma.